Equities research analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will report earnings per share of $6.83 for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $8.23 and the lowest estimate coming in at $5.18. Regeneron Pharmaceuticals posted earnings of $6.84 per share during the same quarter last year, which would indicate a negative year over year growth rate of 0.1%. The business is scheduled to announce its next earnings report on Wednesday, February 5th.
On average, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $23.78 per share for the current financial year, with EPS estimates ranging from $22.26 to $25.34. For the next year, analysts forecast that the firm will post earnings of $26.48 per share, with EPS estimates ranging from $23.33 to $30.55. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share for the quarter, beating the consensus estimate of $5.13 by $1.54. The firm had revenue of $2.05 billion for the quarter, compared to analysts’ expectations of $1.98 billion. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.87 EPS.
Several research firms have recently weighed in on REGN. Canaccord Genuity lowered their price target on Regeneron Pharmaceuticals from $353.00 to $320.00 and set a “hold” rating on the stock in a report on Wednesday, October 9th. Cowen set a $349.00 price target on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, October 8th. Bank of America began coverage on Regeneron Pharmaceuticals in a report on Wednesday, October 16th. They set a “neutral” rating and a $325.00 price target on the stock. Guggenheim raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $355.00 to $403.00 in a report on Monday, September 23rd. Finally, Citigroup raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $340.00 to $420.00 in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $384.74.
Shares of NASDAQ REGN traded down $2.92 during midday trading on Monday, hitting $366.08. 628,013 shares of the stock traded hands, compared to its average volume of 775,720. The firm has a 50-day moving average of $330.36 and a two-hundred day moving average of $306.90. The firm has a market capitalization of $40.51 billion, a P/E ratio of 18.49, a PEG ratio of 1.62 and a beta of 1.19. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.27 and a current ratio of 4.03. Regeneron Pharmaceuticals has a one year low of $271.37 and a one year high of $442.00.
Regeneron Pharmaceuticals declared that its Board of Directors has approved a share buyback program on Tuesday, November 5th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase up to 2.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $370.00, for a total transaction of $370,000.00. Following the sale, the director now directly owns 11,323 shares of the company’s stock, valued at $4,189,510. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Sanofi sold 172,904 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total value of $48,611,959.60. Over the last ninety days, insiders sold 213,923 shares of company stock worth $63,262,696. 11.84% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. HM Payson & Co. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $31,000. Bridger Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $30,000. Coastal Capital Group Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $38,000. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Regeneron Pharmaceuticals by 104.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 143 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 73 shares in the last quarter. Finally, Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $49,000. 66.48% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Golden Cross
Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.